Evidence Hub

Native and synchronous fluorescence spectroscopy for determination of avanafil in presence of its co-formulated drug (dapoxetine hydrochloride): Application to pharmaceutical product, biological fluid and content uniformity

T. Mohamed, S. A. Atty

Spectrochimica Acta Part A - Molecular and Biomolecular Spectroscopy, 2019

15 citations

Abstract

The native and synchronous fluorescence spectroscopy procedures have been established and validated for the simultaneous determination of a binary mixture of dapoxetine hydrochloride (DAP) and avanafil (AVA). The first procedure is based on measurement of native fluorescence intensity of both drugs at λEm 337 nm and 370 nm using λEx 290 nm and 314 nm for DAP and AVA in methanol respectively. The second procedure describes a measurement of synchronous fluorescence intensity of these drugs at 232 nm for DAP, and 267 nm for AVA, using Δλ of 90nm. In the first procedure the fluorescence concentration were 0.1-4.0 μg/mL for DAP and 0.5-16 μg/mL for AVA. For the second procedure fluorescence concentrations were 0.025-1.0 μg/mL and 0.5-16 μg/mL for DAP and AVA respectively, with lower detection limit and quantification limits. The processes were successfully used for the limitation of DAP and AVA in their drug product without pre-separation. Then, the techniques were utilized for the determination of DAP and AVA in biological fluids. There is a good agreement between these results and the results obtained using a reference method.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free